Caladrius Biosciences, Inc. (NASDAQ:CLBS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.96) by $0.08, Morningstar.com reports. Caladrius Biosciences had a negative return on equity of 678.79% and a negative net margin of 84.10%.
Shares of Caladrius Biosciences (NASDAQ:CLBS) traded up 1.28% during trading on Friday, reaching $3.95. The company had a trading volume of 1,288 shares. The firm has a 50-day moving average price of $4.20 and a 200-day moving average price of $4.66. Caladrius Biosciences has a 52-week low of $2.65 and a 52-week high of $7.79.
A number of brokerages recently issued reports on CLBS. HC Wainwright set a $7.00 price target on Caladrius Biosciences and gave the company a “buy” rating in a report on Friday. Zacks Investment Research raised Caladrius Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, ValuEngine raised Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, June 10th.
An institutional investor recently raised its position in Caladrius Biosciences stock. KCG Holdings Inc. raised its stake in Caladrius Biosciences, Inc. (NASDAQ:CLBS) by 74.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,291 shares of the biotechnology company’s stock after buying an additional 15,501 shares during the period. KCG Holdings Inc.’s holdings in Caladrius Biosciences were worth $183,000 as of its most recent filing with the SEC. 6.64% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2801721/caladrius-biosciences-inc-nasdaqclbs-issues-earnings-results-beats-estimates-by-0-08-eps.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.